Physicians treating localized prostate cancer must carefully select patients with higher-volume and high-grade disease for perioperative androgen receptor pathway inhibitors to see meaningful clinical benefits, CancerNetwork reported.
Localized prostate cancer spans a wide spectrum of aggressiveness, both histologically and genomically, ranging from low to intermediate and high risk. Even within the nonmetastatic high-risk cohort, patients fall into low, high, and very high tiers.
Recent trials show that event rates in lower-tier high-risk subgroups are too low for added therapy to make a measurable difference against current standards of care like androgen deprivation therapy plus radiation or surgery monotherapy.
“You have to recognize that localized prostate cancer is a wide spectrum of aggressiveness, histologically as well as genomically, from low to intermediate to high risk,” said Gleave, a distinguished professor in the department of Urologic Sciences at the University of British Columbia in Vancouver, Canada. Martin Gleave, a distinguished professor in the department of Urologic Sciences at the University of British Columbia in Vancouver, Canada, told CancerNetwork.
Gleave pointed out that a patient with a low-volume Gleason grade group 4 cancer and a prostate-specific antigen level of 8 ng per milliliter belongs to a low-tier high-risk group that does not benefit from the PROTEUS regimen. Clinical trials including PROTEUS and the biomarker-directed Genomic Umbrella Neoadjuvant Study (GUNS; NCT04812366), which Gleave runs, specifically enrich for high-volume, high-grade disease.
“Unless you enrich for higher-volume, high-grade cancers, the event rates from treating the lower-tier high-risk subgroup are too low,” Gleave told CancerNetwork.
These protocols require multiple positive cores featuring Gleason pattern 4 or 5 and a prostate-specific antigen level exceeding 20 ng per milliliter as a marker of disease burden. For patients considering surgery, however, clinicians must evaluate whether the disease remains resectable and appropriate for a surgical approach. Systemic therapy cannot make an unresectable tumor resectable, meaning surgical judgment remains critical.